Core Viewpoint - Erasca, Inc. (ERAS) has experienced significant selling pressure, resulting in a 27.2% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - ERAS has an RSI reading of 20.75, suggesting that the heavy selling may be exhausting, indicating a potential rebound [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for ERAS by 1% over the last 30 days, which typically correlates with price appreciation [6] - ERAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, indicating a strong potential for a turnaround [7]

Core Viewpoint - Erasca, Inc. (ERAS) is experiencing significant selling pressure, having declined 24.1% over the past four weeks, but is now positioned for a potential trend reversal as it is in oversold territory and analysts expect better earnings than previously predicted [1] Group 1: Stock Performance and Technical Indicators - The stock's Relative Strength Index (RSI) reading is at 20.63, indicating it is oversold and suggesting a potential reversal in trend [5] - A stock is generally considered oversold when its RSI falls below 30, which helps investors identify entry opportunities for potential rebounds [2][3] Group 2: Earnings Estimates and Analyst Consensus - There is strong agreement among sell-side analysts in raising earnings estimates for ERAS, with a 1% increase in the consensus EPS estimate over the last 30 days [6] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [6] Group 3: Zacks Rank and Investment Potential - ERAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]

Core Viewpoint - Erasca, Inc. (ERAS) is experiencing significant selling pressure, with a 22.9% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analyst expectations of better earnings than previously predicted [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - ERAS has an RSI reading of 21.15, suggesting that heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for ERAS will improve, with a 1% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6] - ERAS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a near-term turnaround [7]

Core Viewpoint - Erasca, Inc. is participating in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its focus on therapies for RAS/MAPK pathway-driven cancers [1] Company Overview - Erasca is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies specifically for patients with RAS/MAPK pathway-driven cancers [3] - The company was co-founded by pioneers in precision oncology and RAS targeting, aiming to create novel therapies and combination regimens to effectively shut down the RAS/MAPK pathway [3] - Erasca has developed one of the most comprehensive pipelines focused on the RAS/MAPK pathway in the industry, supported by a scientific advisory board of leading experts [3] Event Participation - Management will present at the conference on January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one investor meetings [1] - A live audio webcast of the event will be available on Erasca's website, with an archived replay accessible for 30 days post-event [2]

Shares of Erasca, Inc. (ERAS) have been struggling lately and have lost 9.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for th ...

Financial Position - Cash, cash equivalents, and marketable securities totaled $463.3 million as of September 30, 2024, up from $322.0 million as of December 31, 2023, providing a runway into H1 2027[5] - Total assets increased to $528.9 million as of September 30, 2024, compared to $395.3 million as of December 31, 2023[9] - Accumulated deficit reached $(735.4) million as of September 30, 2024, compared to $(606.0) million at the end of 2023[9] Expenses - Research and Development (R&D) expenses increased to $27.6 million for Q3 2024, compared to $25.2 million for Q3 2023, driven by clinical trial and preclinical study costs[5] - General and Administrative (G&A) expenses were $9.6 million for Q3 2024, slightly up from $9.4 million in Q3 2023[6] Net Loss - Net loss for Q3 2024 was $31.2 million, or $(0.11) per share, compared to a net loss of $30.4 million, or $(0.20) per share, in Q3 2023[6] Clinical Trials and Development - The SEACRAFT-2 Phase 3 trial is expected to report randomized dose optimization data in 2025, targeting NRAS-mutant melanoma[4] - IND filings for ERAS-4001 (pan-KRAS inhibitor) are anticipated in Q1 2025, with initial Phase 1 data expected in 2026[4] - IND filing for ERAS-0015 (pan-RAS molecular glue) is expected in H1 2025, with initial Phase 1 data also anticipated in 2026[4] - The company has confirmed potential best-in-class profiles for both ERAS-0015 and ERAS-4001, supporting their development[2]

Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ...

Company Overview - Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers [3] - The company aims to "erase cancer" by creating novel therapies and combination regimens that comprehensively target the RAS/MAPK pathway [3] - Erasca has one of the most extensive pipelines in the industry dedicated to the RAS/MAPK pathway, supported by a scientific advisory board of leading experts [3] Upcoming Events - Erasca will participate in the Guggenheim Securities Healthcare Innovation Conference from November 11 to 13, 2024, with a fireside chat scheduled for November 12 at 2:00 pm Eastern Time [2] - The company will also attend the Jefferies London Healthcare Conference from November 19 to 21, 2024, with a presentation on November 20 at 12:30 pm Greenwich Mean Time [2] - Additionally, Erasca will be part of the 7th Annual Evercore HealthCONx Conference from December 3 to 5, 2024, featuring a fireside chat on December 4 at 11:15 am Eastern Time [2] - Live audio webcasts of these events will be available on Erasca's website, with archived replays accessible for 90 days post-event [2]

In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated SEACRAFT-2 registrational trial in patients with NRASm melanoma; randomized data for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025 Robust balance sheet with cash, cash equivalents, and marketable securities of $460 million as of June 30, 2024 is expected to fund operations into H1 ...

scientific advisory board which includes the world's leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer. Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathwaydriven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomized Stage 1 readout for naporafenib plus trametinib vs. trametinib mon ...